Boston Scientific (NYSE:BSX) recalled the Fetch 2 aspiration catheter it acquired from Bayer (ETR:BAYN) in 2014, after receiving complaints of shaft breakage during coronary thrombectomy procedures. There were no injuries or deaths reported from the shaft breakage and there is no risk to patients who have already had thrombectomies using the Fetch 2 device, Marlborough, Mass.-based Boston Scientific said. […]
Atherectomy
PAD: FDA clears new orbital atherectomy device from Cardiovascular Systems
Cardiovascular Systems recalls some Diamondback devices on embolism risk
AtheroMed wins 510(k) clearance for atherectomy catheter
AtheroMed secured 510(k) clearance from the FDA for its Phoenix device, an atherectomy catheter used for treating peripheral artery disease.
The low-profile catheter aims to minimizes vessel interaction and designed to be easy to set up. The Phoenix system features front-cutting technology that cuts while clearing away clearing debris with an internal Archimedes screw, which runs the length of the catheter. The device is available in a variety of sizes, according to a press release.
AtheroMed closes in on $4.5M for PAD treatment
AtheroMed is closing in on a $4.5 million fundraising round, offering debt and options offering, SEC documents show.
The Menlo Park, Calif.-based medical device company has so far raised $4.3 million for its operations, according to a regulatory filing.
Stealthy AtheroMed raises $6M for peripheral atherectomy device
AtheroMed said it’s raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.